What Is Fluconazole Used For? Uses & Side Effects

Fluconazole is an antifungal medication prescribed to treat and prevent a wide range of fungal infections, from common vaginal yeast infections to life-threatening bloodstream infections and fungal meningitis. Available since 1990, it remains one of the most widely used antifungals in the world, largely because it can be taken by mouth, absorbs extremely well, and reaches tissues that many other antifungals cannot easily penetrate. Its uses span a surprisingly broad spectrum, though the drug also carries real risks that depend on dose, duration, and individual health factors.

How Fluconazole Works

Fungal cells rely on a molecule called ergosterol to keep their cell membranes intact and functional, much the way human cells depend on cholesterol. Fluconazole blocks an enzyme involved in making ergosterol. When that enzyme is shut down, the fungal membrane loses its structural integrity and becomes leaky, which ultimately kills the cell or stops it from growing.¹ Because human cells use cholesterol rather than ergosterol, fluconazole is far more toxic to fungi than to human tissue, which is one reason it can be taken at relatively high doses with a manageable side-effect profile.

One feature that sets fluconazole apart from many other antifungals is its pharmacokinetics. Oral bioavailability exceeds 90 percent, meaning nearly all of the drug you swallow reaches the bloodstream. It also diffuses readily into cerebrospinal fluid, saliva, sputum, skin, and urine.² That cerebrospinal fluid penetration is especially important because it makes fluconazole one of the few antifungals capable of treating fungal infections in the brain and spinal cord.

Vaginal Yeast Infections

The single most common reason fluconazole is prescribed is uncomplicated vaginal candidiasis, the familiar “yeast infection.” For most cases caused by susceptible Candida species, a single 150 mg oral dose is the standard treatment. Trials have consistently shown this to be as effective as multi-day courses of topical antifungal creams, with the obvious convenience of one pill instead of a week of messy vaginal applications.³ In one comparative trial, clinical effectiveness at short-term follow-up reached 80 percent for a single dose of fluconazole, compared with about 72 percent for intravaginal clotrimazole.⁴ A Japanese study reported cure or improvement rates above 95 percent at four weeks after a single 150 mg dose.⁵

For women who get recurrent yeast infections (typically defined as four or more episodes a year), doctors often prescribe a longer regimen: a loading course followed by weekly 150 mg doses for up to six months. This suppressive approach keeps fungal counts low, though infections frequently return once the maintenance course ends.

Oral Thrush and Esophageal Candidiasis

Candida infections in the mouth (thrush) and esophagus are especially common in people with weakened immune systems, including those living with HIV, patients on chemotherapy, and organ transplant recipients on immunosuppressant drugs. Fluconazole is a first-line treatment for both conditions. For oral thrush, typical doses range from 100 to 200 mg daily for one to two weeks. Esophageal candidiasis usually calls for higher doses, often 200 to 400 mg daily, and a longer course of two to three weeks.

These mucosal infections can be extremely uncomfortable, causing painful swallowing and difficulty eating. Before fluconazole became available, treatment options for esophageal candidiasis were largely limited to intravenous amphotericin B, a drug notorious for severe side effects. Having an oral medication that patients could take at home was a meaningful shift in how these infections were managed.

Invasive Candidiasis and Bloodstream Infections

When Candida enters the bloodstream (candidemia) or invades deep organs, the stakes rise dramatically. Fluconazole has been a mainstay of treatment for invasive candidiasis since the early 1990s and remains a first-line drug when the infecting species is known to be susceptible.⁶ Case reports and uncontrolled studies have also described successful use for Candida infections of the joints, eyes, heart valves, and the lining of the abdomen.⁶

In recent years, a class of antifungals called echinocandins (drugs like anidulafungin and caspofungin) have become the preferred initial therapy for candidemia in many guidelines, particularly in critically ill patients. One trial found anidulafungin produced a significantly higher response rate than fluconazole in patients with candidemia caused by Candida albicans.⁷ However, once a patient is clinically stable and the Candida species tests susceptible, many clinicians switch from an intravenous echinocandin to oral fluconazole to complete the treatment course at home. A propensity-matched study found no significant difference in 60-day mortality between fluconazole and echinocandins when the Candida species was susceptible.⁸ For certain species like Candida parapsilosis, which are naturally less susceptible to echinocandins, fluconazole may actually be preferred from the start, with studies showing comparable outcomes.⁹

Cryptococcal Meningitis

Cryptococcal meningitis is a fungal infection of the brain lining that mainly affects people with advanced HIV. It remains a leading cause of death among HIV-positive individuals in sub-Saharan Africa. Fluconazole plays a critical role in managing this disease, particularly in the maintenance phase. A landmark trial in AIDS patients showed that daily fluconazole after initial treatment slashed the recurrence rate of cryptococcal infection from 37 percent on placebo to just 3 percent.¹⁰ That maintenance therapy essentially keeps the infection suppressed for as long as the patient’s immune system remains compromised.

Fluconazole has also been tested at very high doses (1,200 to 2,000 mg daily) as a primary treatment for cryptococcal meningitis in settings where intravenous amphotericin B is unavailable. While high-dose fluconazole is less effective than amphotericin, it offers a crucial alternative in resource-limited areas where intravenous drug administration is not feasible.¹¹ Current WHO guidelines incorporate fluconazole as part of combination regimens for initial treatment and recommend it as the standard for long-term suppressive therapy.

Coccidioidomycosis and Other Fungal Infections

Beyond Candida and Cryptococcus, fluconazole is used against coccidioidomycosis (valley fever), a fungal infection caused by inhaling spores of Coccidioides found in desert soils of the southwestern United States, Mexico, and parts of Central and South America. Clinical practice guidelines recommend fluconazole at 400 mg daily or higher as first-line therapy for most forms of coccidioidomycosis, including the meningeal form, where its ability to cross into cerebrospinal fluid is especially valuable.¹² One persistent challenge is that relapse after stopping therapy is common, so many patients with severe or meningeal coccidioidomycosis take fluconazole indefinitely.¹³

Preventing Fungal Infections in High-Risk Patients

Fluconazole is not only used to treat existing infections. It is widely prescribed as prophylaxis, a preventive measure, in people whose immune systems are severely suppressed. Cancer patients undergoing chemotherapy or bone marrow transplants are particularly vulnerable to invasive fungal infections, which carry high mortality rates. A meta-analysis of randomized controlled trials found that fluconazole prophylaxis reduced the risk of oral fungal infections by roughly 70 percent compared with placebo in cancer patients receiving chemotherapy, radiotherapy, or immunotherapy.¹⁴

A large Canadian trial in patients with acute leukemia or those undergoing bone marrow transplant found that fluconazole prophylaxis significantly reduced both superficial and invasive fungal infections, as well as deaths attributable to invasive fungal infection.¹⁵ The patients who benefited most were those receiving the most intensive chemotherapy regimens.

Common Side Effects

At the single doses or short courses used for vaginal yeast infections, fluconazole is generally well tolerated. The most frequently reported side effects are gastrointestinal: nausea, abdominal discomfort, and sometimes diarrhea. Headache is also common. These tend to be mild and self-limiting. Skin rash occurs occasionally and usually resolves on its own, though any rash should be reported to a prescriber since severe skin reactions, while rare, can occur.

Longer courses and higher doses bring a different side-effect profile, and some of those effects deserve closer attention.

Liver Effects

Fluconazole can affect liver function, and this is the most important side effect to understand for anyone taking it beyond a one-time dose. Elevations in liver enzymes occur in roughly 1 to 10 percent of patients, though the majority of these are mild and temporary, resolving once the drug is stopped.¹⁶ About 0.7 percent of patients experience elevations serious enough to warrant stopping the medication.¹⁶ In a case report, a patient with pre-existing liver problems developed worsening liver function as early as the second day of fluconazole therapy, with values returning to normal after the drug was stopped.¹⁷

If you already have liver disease, your doctor will likely monitor liver blood tests during treatment. People living with HIV appear to be at somewhat higher risk for fluconazole-related liver problems, possibly because they tend to take the drug for longer periods and at higher doses.¹⁷

Heart Rhythm Concerns

Fluconazole can prolong the QT interval, a measure of electrical activity in the heart. A prolonged QT interval raises the risk of a dangerous irregular heartbeat called torsade de pointes. An analysis of the FDA’s adverse event database found that among all reported side effects of triazole antifungals, the rate of QT prolongation or torsade de pointes was around 2 percent, and the signal was statistically significant compared with other drugs.¹⁸

In practice, this risk is most relevant when fluconazole is combined with other QT-prolonging medications. A study of patients receiving both fluconazole and the antibiotic ciprofloxacin found an average QT increase of about 11 milliseconds during combination therapy.¹⁹ Even at the unusually high dose of 1,200 mg daily used for cryptococcal meningitis, one study found a mean QT increase of about 10 milliseconds, with no cases exceeding the 500-millisecond threshold considered most dangerous, though electrolyte imbalances and co-administered drugs still require careful monitoring.²⁰ For a single 150 mg dose for a yeast infection in an otherwise healthy person, this cardiac risk is vanishingly small.

Drug Interactions to Watch For

Fluconazole is a potent inhibitor of certain liver enzymes responsible for metabolizing other drugs, particularly CYP2C9 and CYP3A4. This means it can dramatically increase blood levels of other medications you take, sometimes to dangerous concentrations. The most clinically important interaction involves warfarin, a common blood thinner. Fluconazole blocks the enzyme that clears the more active form of warfarin from the body, which can cause dangerously excessive anticoagulation and bleeding.²¹ If you take warfarin, your prescriber will likely need to adjust your dose and monitor your blood clotting more frequently while you are on fluconazole.

Other drugs affected include certain diabetes medications (like sulfonylureas, where fluconazole can cause dangerously low blood sugar), some seizure medications like phenytoin, the immunosuppressant cyclosporine, and certain statins. Even over-the-counter drugs can interact. Always tell your prescriber and pharmacist about everything you take, including supplements, before starting fluconazole.

Pregnancy

Whether fluconazole is safe during pregnancy has been studied extensively, and the answer is genuinely nuanced. A single 150 mg dose for a yeast infection during the first trimester does not appear to meaningfully increase the overall risk of birth defects. A large Danish cohort study found no significant increase in the overall prevalence of birth defects among fluconazole-exposed pregnancies after adjusting for confounders. However, a small but statistically significant increase in the risk of one specific heart defect, tetralogy of Fallot, was observed.²²

A recent systematic review and meta-analysis confirmed that fluconazole use during the first trimester did not significantly increase the overall risk of major birth defects when adjusted estimates were combined. But it flagged a potential signal at cumulative doses above 150 mg and a significant association with miscarriage.²³ A US cohort study also found a modestly elevated risk of musculoskeletal malformations associated with first-trimester fluconazole exposure, an effect that grew stronger at higher cumulative doses.²⁴

The upshot: most guidelines recommend topical antifungal treatments rather than oral fluconazole for yeast infections during pregnancy, especially in the first trimester. When oral fluconazole is medically necessary for a serious fungal infection during pregnancy, the decision involves weighing a small, dose-dependent increase in risk against the danger of the untreated infection.

Use in Children

Fluconazole is used across the pediatric age range, including in premature newborns. A systematic review covering more than 4,200 pediatric patients found it to be relatively safe, with no statistically significant difference in overall adverse events compared with placebo or other antifungals.²⁵ The most common side effects in children, as in adults, involved the liver and gastrointestinal tract. Among neonates specifically, liver-related effects accounted for the vast majority of recorded adverse events, reinforcing the need for monitoring in this vulnerable population.²⁵ In premature infants in the NICU, prophylactic fluconazole has been shown to reduce the incidence of invasive candidiasis, a potentially fatal complication in that setting.

The Growing Problem of Resistance

One of the most significant challenges facing fluconazole today is fungal resistance. Some Candida species, particularly Candida krusei and many strains of Candida glabrata (now reclassified as Nakaseomyces glabratus), are inherently less susceptible or outright resistant to fluconazole. Even among normally susceptible species like Candida albicans, resistance can develop during prolonged exposure, especially in immunocompromised patients who take the drug for months or years. Resistance mechanisms include increased pumping of the drug out of the fungal cell, changes to the target enzyme so fluconazole can no longer bind effectively, and workaround pathways that allow the fungus to produce ergosterol by alternate routes.²⁶

This is one reason why susceptibility testing matters for serious infections. Treating a bloodstream infection with fluconazole when the Candida species is resistant wastes time and can be fatal. The rise of Candida auris, a multi-drug-resistant species that has spread globally in healthcare settings, has further highlighted the limitations of fluconazole, since most C. auris isolates are resistant to it. For routine vaginal yeast infections caused by Candida albicans, resistance is still uncommon, so fluconazole remains highly effective for most people in that context.

How Fluconazole Came to Be

Fluconazole was developed by Pfizer researchers in the 1980s specifically to fill a gap in antifungal therapy. The goal was a broad-spectrum drug that could be given both orally and intravenously for infections ranging from skin-level nuisances to life-threatening systemic disease.²⁷ Before fluconazole, the antifungal landscape was dominated by amphotericin B (effective but highly toxic and available only by IV) and ketoconazole (oral but with significant liver toxicity and hormonal side effects). Fluconazole’s combination of oral bioavailability, tissue penetration, and tolerability was genuinely novel for its time, and its arrival coincided with the peak of the AIDS epidemic, when fungal infections were a major cause of illness and death. Its patent expired long ago, so it is now available generically and at very low cost in most countries, which has kept it in widespread use even as newer and sometimes more potent antifungals have come along.